Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do - Healthcare Research Wed, 15 Aug 2018 19:41:50 Global Diagnostic Neuroimaging Markets and Emerging Applications, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9B6-01-00-00-00 The scope of this research study covers the diagnostic applications of advanced imaging in neurological and neurodegenerative disorders. The geographical market covered is North America (US), Europe, and Asia-Pacific (APAC).--BEGIN PROMO--

Key Features

This research service provides the following metrics:

  • A quantification of the size of procedure volumes for select neurology disorders (Alzheimer’s disease, Epilepsy, Parkinson’s disease, Multiple Sclerosis, Stroke and Brain Tumor) for the above-mentioned markets from 2017 to 2022
  • Market forecasts presenting the incidence and prevalence population for neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis
  • Insight into brain imaging and neuroimaging technologies, insights into technology trends, future diagnostic and therapeutic perspectives, and competitive landscape
  • Diagnostic imaging procedure volumes and service market revenue estimates for select neurology disorders (Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, Stroke and Brain Tumor) for the base year 2017
  • Key insights on recent advancements in neuroinformatics initiatives and novel platforms shaping the future, including Artificial Intelligence (AI) applications in neuroimaging focusing on new advancements and future developments.
  • Current key products and solutions offerings in neuroimaging software applications
  • Growth opportunities and companies to action section that enlists the key roles that can be taken up by companies for growth along with an illustrative list of key company profiles including GE Healthcare, Philips Healthcare, Siemens Healthineers, Canon Medical Systems, Ricoh, Hitachi, and Shimadzu

Key Issues Addressed

  • What are some of the major neurological disorders burdening the society today and what potential treatments and breakthroughs can be expected in the near future?
  • What major imaging modalities make up the neuroimaging market and what is the proportion of imaging techniques used for diagnosis and treatment of key neurological disorders?
  • What is the estimated neuroimaging procedure volume and service market revenue of imaging technologies for different geographies like North America, Europe, and APAC?
  • Are the vendors in the space ready to go it alone or do they need partnerships to take their businesses to the next level? Are there any novel start-ups and/or products?
  • How is the role of neuroimaging technologies and solutions in the diagnosis and treatment pathways for neurological disorders changing? What are the current gold standards? How will future imaging technologies play a role to overcome the neurological disorders challenge, especially neurodegenrative disorders like Alzheimer's and Parkinson’s?
  • Are the products and services offered today meeting customer needs or is additional development needed e.g., in neuroinformatics? Have Artificial Intelligence (AI) and machine learning started making an impact in neuroimaging? Are there any growth opportunities?
Mon, 13 Aug 2018 00:00:00 +0100
RNA Technologies Empowering Small Molecule Therapeutics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-20-00-00 This Drug Discovery TOE highlights the innovations in small molecule therapies targeting RNA. The key technology trends highlighted include in-silico assays, RNA drugs, nanoparticle delivery platforms, and a clinical trial summary of small molecule therapies targeting RNA. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: RNA-modifying enzymes, targeted small molecules, RNA therapy, short hairpin RNA, mRNA, RNAi, nanoparticle therapy, rare disease therapy, splicing Fri, 10 Aug 2018 00:00:00 +0100 Innovations in Therapeutic Approach for Cystic Fibrosis http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-86-00-00 This Genetic Technology TOE depicts life sciences trends across cystic fibrosis. First-in class mRNA therapeutics with targeted delivery, novel cell types, lentiviral gene therapy, and RNA vaccines, among other therapies are profiled. Clinical trials of RNA vaccines for the cancer treatment are also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: mRNA therapeutics, targeted delivery, cell types, lentiviral gene therapy, RNA vaccines Fri, 10 Aug 2018 00:00:00 +0100 Innovations in Digital and Targeted Treatment Platforms http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-85-00-00 This Genetic Technology TOE depicts new life sciences trends across digital targeted therapeutic platforms. Human genetics, antibody therapies, digital oncology platforms, among others, are profiled. The clinical trials scenario for FoundationOne Platform is along depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Digital therapy, human genetics, oncology, digital oncology, antibody, precision medicine Fri, 3 Aug 2018 00:00:00 +0100 Analysis of Western European Molecular Imaging Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD6E-01-00-00-00 This study takes a look at the Western European molecular imaging industry. The geographic scope of the market includes the United Kingdom, Germany, Italy, Spain, France, Scandinavia, and Benelux. The market is expected to experience a compound annual growth rate (CAGR) of 4.5 percent during 2017 to 2022, primarily driven by the growing incidence of cancer - with breast cancer and lung cancer being the most common cancers - and the continuing shift from single modalities to hybrid imaging. France, Germany, and Italy are hotspots for immediate future, followed by the steadily growing markets of Spain, Scandinavia, and Benelux. Apart from the rising incidence of cancer, the greater availability of novel radiotracers and higher quantitation will drive the molecular imaging market. On the other hand, the price sensitivity of purchasers due to insufficient reimbursement and competition from other imaging modalities will continue to restrain growth. France is the fastest growing market in Western Europe due to its high gross domestic product (GDP) spending on oncology screening programs. Italy and Germany are expected to be the second and third fastest due to the high incidence of cancer and increasing government initiatives. Spain, Benelux, and Scandinavia are forecast to grow steadily, while the United Kingdom is likely to be the slowest due to budgetary constraints. There has been greater focus on PET/CT systems over SPECT/CT over the last few years and this trend will continue in the forecast period. Top market participants are anticipated to continue placing greater emphasis on premium modalities. The PET/CT segment will experience the highest growth, while more stable growth is expected for the SPECT/CT segment. The latter segment has shrunken due to past shortages of Tc-99m, concerns over stability of future supply, improvements in PET MPI, and lower quantitation accuracy than PET. However, over the last few years, improvements in its technology and quantitation accuracy is expected to drive growth. SPECT/CT has traditionally been used for cardiac imaging, while PET/CT has primarily been used for oncology imaging. This is set to change as advancements in PET/CT and SPECT/CT technologies, coupled with the launch of novel radiopharmaceuticals, will see molecular imaging applied across new clinical areas such as orthopedics and neurology. Wed, 1 Aug 2018 00:00:00 +0100 Innovations in X-rays, Sonar, Ultrasound, Imaging Systems, and CT Scans http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-22-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations in the medical imaging and diagnostics industry. Some of the profiles covered include development of colored X-rays, artificial iris, next generation cancer imaging system, 3D nano-imaging, low-dose CT scan, and novel X-ray instrumentation. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Colored X-rays, artificial iris, cancer imaging system, 3D nano-imaging, low-dose CT scan Fri, 27 Jul 2018 00:00:00 +0100 Recent Advances in Management of Rare Disease http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-84-00-00 This Genetic Technology TOE depicts new life sciences trends across rare disease management through gene therapy approaches. The corresponding clinical trials scenario for lysosomal storage diseases is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Ex Vivo gene therapy, lysosomal storage disease, rare diseases, genetic disorders, lentiviral therapy, Fabry's disease, Sanfilippo's syndrome, Niemann-Pick disease Fri, 27 Jul 2018 00:00:00 +0100 Global X-ray Mammography Imaging Systems Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDD4-01-00-00-00 Over the last 20 years, hospitals and imaging centers in developed economies have adopted X-ray mammography equipment to screen and diagnose breast cancer. This has led to significant reduction in mortality and prompted emerging countries to invest in population-based, organized screening. Significant investments in mammography technology have paved the way for radiation safety, patient comfort, and 3D imaging that provides precise tumor detection. Market measurements revenue and year-over-year growth rate by region and segment are analyzed for 2015 to 2016 and forecast until 2022. Pricing range and growth trend by sub-segment is discussed for the base year. An extensive list of manufacturers in the X-ray mammography space to watch out for in 2017 is also provided. X-ray mammography is the gold standard for breast cancer detection. Due to the rising incidence of breast cancer, organized population-based screening programs are carried out in Western countries at a 1-to-3-year screening interval, depending on country policies. Starting in early 1990, the countries have witnessed a significant decrease in mortality. Mammography was not considered patient friendly due to discomforts caused, possible false positives, overlooked tumors and the potential radiation exposure. However, with innovations in technology focusing on microcalcification, sensitivity, specificity, use in dense breast tissue patients, most western countries have switched to full-field digital mammography. However, reimbursements deter the adoption of digital breast tomosynthesis for screening programs With the advent of private hospitals and favorable reimbursement health insurance, there is more demand for patient safety and quality of technologies, reduced hospitalization and reduction in overall healthcare costs in Asia-Pacific. Globally, countries are placing emphasis on early detection of breast cancer safety and investing in screening programs. Business models focusing on managed services, pay per use , sharing services, integrated workflow and automation are changing the landscape of the mammography procurement. These factors determine the growth of the mammography market. Strategies, growth analyses, competitive landscape, and future focus are discussed for vendors, such as GE Healthcare, Siemens Healthineers, Hologic, IMS, Planmed, Carestream, Agfa, Fujifilm, Allengers, Cura Healthcare, and Konica Minolta, among others. The base year for the study is 2017; the historic years are 2015 and 2016; the forecast period is from 2018 to 2022.--BEGIN PROMO--

Research Scope

This study aims to analyze and forecast the X-ray Mammography Imaging Systems market in North America (US and Canada), Europe, and Asia-Pacific for 2017. Market trends analyzed include utilization of mammography systems, breast care statistics, mammography procedure volume analysis, and clinical layout of breast care in countries presented in research scope, growth indicators, market adoption and penetration, factors influencing RoI, critical unmet needs and potential game-changing strategy, growth opportunities for X-ray mammography,  technology trends driving X-ray mammography growth, future prospects, product profile, competitive structure, market metrics market share,  revenues, and strategy.

Regions Covered:

  • North America (the United States and Canada)
  • Europe: Western Europe (Germany, the United Kingdom, Italy, France, Spain, Benelux, Scandinavia);  Eastern Europe (Hungary, Poland and Romania)
  • Asia-Pacific (China, India and Japan )

Analyses by analog, computed, 2D digital, 2D digital to DBT upgrade and digital breast tomosynthesis are provided for the three regions. 

 

Wed, 25 Jul 2018 00:00:00 +0100
Innovations in Orthobiologics, Artifcial Intelligence in Medical Diagnosis, Non-invasive Health Monitoring, and Cybersecurity for Medical Devices http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-1F-00-00 The latest edition of Medical Device TOE profiles innovations in orthobiologics, artificial intelligence in medical diagnosis, non-invasive health monitoring, and cybersecurity for medical devices. Innovations in focus include a supercomputer to understand the functioning of the brain, ECG patch for atrial fibrillation diagnosis, through-the-skin monitoring of renal function, bone-grafting technology using small peptides, and use of machine vision and artificial intelligence for faster blood testing. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Orthobiologics, artificial intelligence, non-invasive health monitoring, cybersecurity, ECG patch, atrial fibrillation diagnosis, renal function, bone-grafting, peptides Fri, 20 Jul 2018 00:00:00 +0100 Novel Therapeutic Approaches for Treatment of Cancer http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-83-00-00 This Genetic Technology TOE depicts new life sciences trends across cancer treatment. Innovations related to the development of novel therapeutic approaches for the treatment of cancer, including senescent cells, CAR-T cell therapy, epitranscriptomics, and exosome production disruption, are profiled. The corresponding clinical trials scenario is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cancer, senescent cells, ageing, CAR-T cell therapy, solid tumors, epitranscriptomics, cancer metastasis, exosome production Fri, 20 Jul 2018 00:00:00 +0100 US Medical Marijuana Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K27E-01-00-00-00 The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal level, marijuana is still considered an illegal Schedule 1 drug. Individual states, however, have laws in place for the legal use of medical marijuana, and in some states, for the use of recreational marijuana. Cannabidiol (CBD) products are also legally available in some US states as well as in many other countries. The market generates a lot of money, though much of that money is still considered a black market. Many business segments are involved with the development of the medical marijuana market. Some businesses directly touch the plant product, such as growers, packers, transporters, and sellers. Other businesses operate in the medical marijuana industry but do not touch the plant product, including legal services, marketing and brand services, data and analytical services, insurance participants and hardware or software companies. The rules differ depending upon where a company stands related to the marijuana plant. This is a very different model than is in place for traditional pharmaceutical products. The medical marijuana segment of the marijuana industry includes marijuana plant products, CBD products, and synthetically derived products targeting the cannabidiol receptors CB1 and CB2. There are several synthetic products currently on the markets in many countries other than the US. As a matter of fact, in Canada, not only is medical marijuana approved for use on the national level, its use is covered by Health Canada, the national government insurance plan. In the US, medical marijuana use is increasing, as many more states have approved it for use in several diseases. In addition, hundreds of clinical trials are underway, testing products under the watchful eye of the FDA. It has been reported in states where medical marijuana is approved for use for the treatment of pain, there have reductions in the use of opioid drugs. This decrease in opioid use may prove to be a valuable mechanism to curb the current opioid epidemic in the US. Legal uncertainty related to the use of medical marijuana has limited big pharma investments into this space; however in non-US locations, companies are more interested in pursuing this area of research and development. Billions of dollars are being generated through this market. It is a growing market drawing keen interest from physicians, investors and regulators. Physician education will be crucial, as these products gain approval, as cannabis was not a part of the medical curriculum of many currently practicing physicians. Wed, 18 Jul 2018 00:00:00 +0100 Innovations in Biopharmaceutical Treatments http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-1F-00-00 This Drug Discovery TOE depicts trends across biopharmaceuticals for psoriasis, hepatocellular carcinoma, Crohn's disease, migraine, HIV, and hepatitis B infection, among others. Clinical trial analysis of Etanercept biosimilar is also presented. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biopharmaceuticals, FDA-approved drugs, psoriasis treatment, Ramucirumab, hepatocellular carcinoma, monoclonal antibody, Crohn s disease, calcitonin gene-related peptide, drug targets, migraine prevention, multi-drug resistant HIV infection, biologics manufacturing, biosimilar commercialization, X-linked hypophosphatemia, immunotherapy, hepatitis B Fri, 13 Jul 2018 00:00:00 +0100 Recent Advances in Precision Medicine Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-82-00-00 The Genetic Technology TechVision Opportunity Engine (TOE) depicts the current landscape and the new life sciences trends across precision medicine. Precision medicine strategies targeting mRNA splicing, novel therapies for inherited disorders, microbiome-based therapies for inflammatory diseases, and gene editing technologies fueling personalized medicine are detailed. Clinical trials scenario related to CRISPR-based technologies is also depicted. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Precision medicine, mRNA splicing, inherited deafness, microbiome-based therapy, inflammatory bowel disease, gene editing, CRISPR Fri, 13 Jul 2018 00:00:00 +0100 Global Digital Health Outlook, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K262-01-00-00-00 At the beginning of this decade, Frost & Sullivan invented the definition of Digital Health to include convergent market segments, such as healthcare information technology (HCIT), remote patient monitoring (RPM), mobile health (mHealth), and telemedicine. Over the last five years, these segments have become increasingly sophisticated as new technologies have made their way into healthcare. The industry will see a rapid dissolution of segment boundaries as technologies such as mHealth, analytics, cloud, and telemedicine are integrated across the board. While technology diffusion may be passive in some areas, industry regulations that focus on value and innovation drive a large part of the transformation. Value-based care transformations are a crucial motivation for investments in technologies that enable cost reduction, benefits maximization, and transparency. The abundance of opportunities for new solutions, services, and business models that can be brought into healthcare makes this space exciting and lucrative for all types of businesses. Fundamental industry paradigms are changing, not because of the increasing participation of non-healthcare companies (especially technology vendors) in healthcare, but because of the new attitude they bring to organizational workflows and consumer experiences in the industry. At the country level, the philosophy of global governments relating to healthcare could spark, sustain, or delay momentum in terms of funding, coverage, and technology enhancements. This report cites examples in the United States, China, India, Japan, Australia, and Southeast Asia, where current government policies will have significant impact on healthcare costs, quality, and access. Learn more about Frost & Sullivan s current views on digital health here at http://digitalhealth.frost.com.--BEGIN PROMO--

Research Scope

This report captures both important trends and predictions impacting the industry now as well as presents topline forecasts for the global digital health market. The report discusses healthcare trends by region based on increasing interest in digital health worldwide. In addition, this report presents information on important companies, both established and new, chosen by Frost & Sullivan’s analyst team to highlight as companies to watch.

Presented Segmentation:

  • Digital Health Market
  • Total Market
  • Health IT
  • Telehealth

Regional Segmentation:

  • Global
  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Key Issues Addressed

  • What are the leading areas of growth opportunity in digital health in 2018?
  • What are the current healthcare trends across the global markets that could apply to digital health?
  • What does the market forecast for digital health, HCIT, and telehealth look like now and in the future?
  • What is the current interest in artificial intelligence (AI), digital therapeutics, electronic medical record (EMR) usability, and other factors?
  • What are some important leading vendors to watch in the near term?
  • What are some interesting start-ups operating in global digital health markets?
Tue, 10 Jul 2018 00:00:00 +0100
Actionable Strategy and Roadmap for the Biotechnology and Genomics Industries in India http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298636634 Fri, 6 Jul 2018 05:17:27 +0100 Influence of Artificial Intelligence on Drug Discovery and Development http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-81-00-00 The Genetic Technology TechVision Opportunity Engine (TOE) outlines the impact of artificial intelligence (AI) on the global drug discovery and development landscape. Berg Health s precision medicine platforms and a clinical overview of the company s pipeline have been profiled in the TOE. Furthermore, IP trends, research aspects, and AI-medicine strategies have also been described. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Artificial intelligence, drug discovery, drug development, precision medicine Fri, 6 Jul 2018 00:00:00 +0100 Novel Therapies for Rare and Genetic Diseases http://www.frost.com/prod/servlet/sublib/display-report.do?id=D819-01-00-00-00 Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being proposed to treat them. Moreover, human stem cell therapy is suggested as one of the most promising alternatives. Furthermore, genetically modified stem cells and autologous induced pluripotent stem cells, synergistically coalesced with zinc-finger proteins and transactivator-like effector nucleases, are targeted as the selection of choice for the ex vivo repair of specific mutated deoxyribonucleic acid (DNA) sequences. Similarly, patient specific induced pluripotent stem cells can be edited and shifted back into the patient, leading to a new approach to precision medicine. In addition, once homed, stem cells secrete a vast number of paracrine factors that could become new therapeutic tools in the treatment of rare and genetic diseases. Therefore, next-generation small molecules, gene therapy, stem cell therapy, and gene editing for DNA repair are promising approaches to the treatment of rare and genetic diseases. This research service (RS) depicts the current landscape and the new trends in the development of novel therapies for rare and genetic diseases, focused on highly interrelated and synergistic approaches. Fri, 29 Jun 2018 00:00:00 +0100 Micro-LED R&D Portfolio Analysis and Roadmapping http://www.frost.com/prod/servlet/sublib/display-report.do?id=D81F-01-00-00-00 Micro-LEDs (or Micro LEDs) are a next-gen self-emissive low power display technology with superior image quality compared to conventional display technologies such as organic light emitting diode (OLED) displays and liquid crystalline displays (LCDs). The key R&D focus area is mass transfer technology which enables commercialization and mass production of micro-LEDs. GaN-on-Si is emerging as a potential technology enabling mass-manufacturing of micro-LEDs. Micro-LED technology enables integration of sensor components layered on the display panel, resulting in more compact and efficient interactive displays. High growth opportunities are observed for display and semiconductor manufacturers. Micro-LEDs can be also used in advanced sensing applications and next-gen communication techniques such as visible light communication (VLC). In the short-term, consumer electronics application such as AR headsets and smartwatches are high impact sectors. In the longer term, micro-LEDs will be integrated into healthcare wearables and used for medical applications such as optogenetics. The technology and innovation report covers the following aspects: Significance of Micro-LEDs Applications landscape Key stakeholders and their competitive positioning [application vs innovation matrix] Enviornment analysis: Assessment of R&D Portfolio Areas and Themes Key unmet/market needs Key performance indicators for R&D Success Key drivers and challenges hindering commercialization Insights on research orientation and funding Patent analysis and innovation portfolio areas R&D Pipeline and Applications roadmap R&D and Commercialization strategies Frost & Sullivan s Strategic Viewpoint on Growth opportunities Fri, 29 Jun 2018 00:00:00 +0100 Reimagining Healthcare Delivery: Impact of Gamification and Patient Engagement http://www.frost.com/prod/servlet/sublib/display-report.do?id=D843-01-00-00-00 Healthcare industry has undergone major transformation in the last decade with the incorporation of digital technologies. The changing technological as well as social trends, which focuses more on consumerism of healthcare which includes personalized interventions, making patients more accountable for their healthcare, disease awareness, is aimed towards providing greater quality healthcare at a lower cost. Enabling this changing trend is use of gamified products in the healthcare industry. Gamification in healthcare supports behavioral change in patient population, encouraging self management and better patient engagement. Gamification has positive effect on patients health by promoting adherence to treatment, and increasing motivation to fight diseases. Fri, 29 Jun 2018 00:00:00 +0100 Innovations in Pain Management: A Technology Blueprint to Counter Opiod Addiction http://www.frost.com/prod/servlet/sublib/display-report.do?id=D844-01-00-00-00 Over the past several decades drug therapies for clinically safe and effective management of various types of pain, classified as being acute, chronic, breakthrough, nerve, and bone-related have been treated with the use of opioids, NSAIDS, anticonvulsants and antidepressants. However, increasing reliance on their use for prolonged intervals and side-effects associated with the same have led to an increasing demand for drug-alternatives that can improve or retain quality of life of patients while managing their pain. Medtech developers have been addressing these concerns over the past two decades with the introduction of device-based pain management therapies. This research service focuses on the need for replacing opioids and other drug-based therapies for pain control, and underlying implications for various stakeholders involved in enabling the adoption of such therapies for clinically safe and effective management of pain disorders. The research service covers a snapshot of current industry scenario, including coverage of market growth, top players, major drivers and challenges that are challenging the status quo of companies operating across developed and emerging economies. The chapters also cover gamechanging technologies and research initiatives that drive business performance in competitive portfolios. The research evaluates industry collaborations that are bridging the device-drug gap in treating pain. A comprehensive analysis of value chain and stakeholder concerns along the value stream is evaluated in-depth through voice of stakeholder approach. The research service evaluates the value of care delivered by drug and device therapies prescribed today for managing pain. Fri, 29 Jun 2018 00:00:00 +0100 Innovations in Diabetes Cure, Safer CAR-T Therapy, and Pediatric Genetic Disease Treatment http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-80-00-00 The Genetic Technology TechVision Opportunity Engine (TOE) presents trends across diabetes care, CAR-T cell therapy, pedriatic and genetic disease treatment. Novel solutions for pancreatic islet transplants, CAR-T cell therapy, enzyme replacement therapy, and autism correlations are profiled. Clinical trials scenario for Alzheimer's disease is also depicted. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Diabetes, CAR-T therapy, pediatrics, genetic disease treatment, pancreatic islet transplant, enzyme replacement therapy, fatal genetic disorder, autism, recombinant drugs, Alzheimer s disease Fri, 29 Jun 2018 00:00:00 +0100 Organ-on-a-chip Innovations Fueling Drug Screening Applications http://www.frost.com/prod/servlet/sublib/display-report.do?id=D84A-01-00-00-00 Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human relevant per se but can mimic a wide variety of human functions such as breathing, heart beats, peristalsis, menstruation, neuronal communication. Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human relevant systems. US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others. Fri, 29 Jun 2018 00:00:00 +0100 Internet of Medical Things Enabling Hospitals of the Future http://www.frost.com/prod/servlet/sublib/display-report.do?id=D81A-01-00-00-00 The Internet of Medical Things (IoMT) concept defines a group of medical devices and applications that are interlinked with the healthcare information technology (IT) systems via online computer networks. Medical devices that are integrated with wireless communication technologies provide the benefits of machine-to-machine communication, which is where IoMT comes into play. IoMT devices include a connected ecosystem of sensors and devices tagged around the individual to capture, measure, and identify key data; stratify risks; make decisions; and initiate necessary action plans. The healthcare industry is expected to move from reactive patient care to proactive patient care leveraging IoMT. IoMT supports patients, staff, and healthcare providers at the point of care by the following ways: Exchanging information and combining communication in unmatched ways Distributing the accurate information and resources at the right time Providing boundless opportunities for the growth of smart, efficient, and effective hospital processes. Sensor technology, along with artificial intelligence (AI), Big Data analytics, and Blockchain will drive the adoption of smart hospitals as they provide competitive safety and security advantages and ubiquitous solutions to the patients and as well as the doctor. The smart hospital market is driven by demand for remote patient monitoring and chronic disease management, introduction of advanced smartphones, mobile applications, and fitness devices and advanced hospital infrastructure. Patient data security and privacy concerns, lack of IoT technology skills, and lack of clinical-grade mobile applications have restrained market adoption. Key aspects covered in the technology and innovation report includes the following: Significance of IoMT in the healthcare sector Key technology trends and key enabling technologies Major factors influencing technology development and adoption Profile of key stakeholders and important innovations Growth opportunities based on patent scenario and market potential Profile of business models for sustainable competition Thu, 28 Jun 2018 00:00:00 +0100 Vision 2025 Healthcare in the Smart Home http://www.frost.com/prod/servlet/sublib/display-report.do?id=K247-01-00-00-00 Smart homes are no longer an emerging concept. Consumers are not only warming up to the idea but also buying home automation products. Smart speakers seem to be the favorite, with sales jumping from a meager 6 million units in 2016 to a whopping 33.2 million units in 2017. The developing ecosystem of home automation products that each of these current smart speakers provides is encouraging the sale of related lighting, energy and home security products. Growing alongside this trend is the potential for healthcare services to be provided in a smart home. In fact, several health services being can be integrated with existing smart home infrastructure: telehealth, remote patient monitoring, simple medication reminders, or answers to health information queries. But the true potential of a smart home that offers care lies in identifying the unique health needs of each individual residing in a home from infants or the elderly and serving those unique needs simultaneously. In the future, the true smart home (which will evolve from the current connected home ), and the further evolved intelligent homes will be able to do this with ease, and monitor the entire health and wellness of all residents enabling a proactive approach to care, instead of reactive. For now, the homes can serve the needs of aging-in-place, chronic disease management and post-acute care. Naturally, the current ecosystem is somewhat fragmented, operating in silos. However, a platform integration of multiple health-related services with other non-health, consumer related services will be the next step for most vendors serving this space; for example, motion sensors can automatically turn up the lights for senior grandmother in an aging-in-place scenario.--BEGIN PROMO--

Research Highlights

This study covers the concept of a smart home delivering healthcare, including the services, framework and the technology stack. It also delineates all of the resident profiles and their individual health needs that a smart home must cater to. For each of the application segments mentioned earlier, it covers the features a smart home must have to provide services for those segments. In addition, regional trends and statistics on current connected home penetration across the world have been included. Revenue forecasts for the overall smart home, as well as for the health and wellness ecosystem are provided. In addition to the ecosystem for a care delivering smart home, a spotlight on the key companies to watch in this space has been included. Finally, analyst commentary on business models, future evolution and a glimpse of the smart home providing care has been covered.

Key Issues Addressed

  • Are we really in the age of smart homes? What is the level of consumer interest in the concept? What should a Smart Home Tech Stack comprise for enabling healthcare services?
  • Which healthcare services can be delivered in the smart home, and how will they evolve? What trends are affecting these developments?
  • What are the resident profiles, and their unique health needs in a smart home, that the care delivery services must cater to?
  • Which care delivery segments can be served by a smart home healthcare service, and what features must smart homes have to enable such services?
  • What is the level of regional readiness for smart homes healthcare services? How does that compare to the existing smart home penetration across the world?
  • Who are the players in this ecosystem, which are the key companies to watch? What business models can be leveraged in this space? What does an ideal smart home delivering care look like?
Wed, 27 Jun 2018 00:00:00 +0100
Endoscope Reprocessing Systems and Software Solutions Market Assessment, Australia, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9E6-01-00-00-00 The market for endoscope reprocessing systems and workflow solutions in Australia was worth A$61.1 million in 2017. It is expected to grow at a robust CAGR of 10.1% to reach a market size of A$98.7 million in 2022. The market is segmented into two broad segments, which are then divided into several sub-segments as mentioned below Endoscope reprocessing solutions o Core equipment 1. Automated endoscope reprocessors (AERs) 2. Storage and Drying Cabinets o Consumables 1. Disinfectants and Chemicals 2. Detergents o Support Products 1. Scope Transport Carts (Trays and Trolleys) 2. Flushing Sinks 3. Test Strips 4. Cleaning Products (Wipes, Sponges, Brushes) Workflow Solutions o Integration Software Solutions, and o Track & Trace Solutions The total number of endoscopy procedures in Australia stood at 3.7 million in 2017. They are expected to grow at a CAGR of 6.5% during 2017-2022 to reach 5.1 million in 2022. While flexible endoscopy procedures accounted for 65.3% of the total procedural volume in 2017, the growth in volume will be equally driven by both rigid and flexible procedures growing at almost equal CAGRs of 6.2% and 6.7%, respectively, during 2017-2022. Inpatient settings are still the ones taking up higher loads of endoscopic procedures in Australia, accounting for 67.8% of procedures in 2017. Hospitals are expected to dominate the procedural volumes during the forecast period, albeit at a continuously reducing share, accounting for 64.1% of total procedures in 2022, thus losing ground to outpatient and day care settings. The higher share of hospital-based endoscopy, coupled with growing contribution from outpatient and day care based settings, has led to considerable opportunities for market participants from both end-user types. While hospitals, typically taking care of larger daily volumes, require sophisticated systems and workflow processes in place, day care centers are the ones with smaller volume requirements offering strategic alternatives to market participants in terms of smaller and more effective AER models. Wed, 27 Jun 2018 00:00:00 +0100 Advancements in Biomarker Assays and Stem Cell Therapies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-7F-00-00 The Genetic Technology TechVision Opportunity Engine (TOE) presents trends across biomarker assays and stem cell therapies. A blood test for traumatic brain injury, use of umbilical cord mesenchymal stem cells and adipose-derived mesenchymal stem cells for treatment of liver cirrhosis, and using mesenchymal stem cells for treatment of ulcerative colitis are profiled. The corresponding clinical trials scenario is also depicted. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biomarker assays, stem cell therapies, blood test, traumatic brain injury, umbilical cord mesenchymal stem cells, adipose-derived mesenchymal stem cells, mesenchymal stem cells, ulcerative colitis, liver cirrhosis Fri, 22 Jun 2018 00:00:00 +0100 Advancements in Pressure Sensors, Cancer Diagnosis, Implantable Devices, Drug Discovery, and Humidity Control http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-7F-00-00 This edition of the Inside R&D TOE depicts trends in a series of developments associated with biodegradable pressure sensors for healthcare applications, cancer diagnosis, and implantable devices. It also focuses on innovations in drug discovery and humidity control. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Biodegradable sensors, protein biomarkers, drug discovery, humidity control Fri, 22 Jun 2018 00:00:00 +0100 Innovations in Retinal Scanning, Neural Imaging, Post-operative Imaging, MRI Diagnostics, Breast Cancer Imaging, and Drug Efficacy Assessing Tools http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-21-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations profiles in the medical imaging and diagnostics industry. Some of the profiles covered include development of an MRI without using contrasting agents, combined digital breast screening for cancer diagnosis, artificial intelligence-based breast imaging, automated retinal scanning solution, neural imaging, and surgical site markers for improved post-operative imaging. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Magnetic resonance imaging, medical imaging, breast screening, HIV drugs, retinal scanning, breast imaging, ophthalmic disorders, surgical site markers, near-infrared imaging Fri, 22 Jun 2018 00:00:00 +0100 Endoscope Reprocessing Systems and Software Solutions Market Assessment, United States, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K236-01-00-00-00 Endoscope reprocessing systems and workflow solutions was a $526.6 million market in the United States in 2017. It is expected to grow at healthy CAGR of 8.6% to reach $796.4 million in 2022. The market is segmented into two broad segments which are then divided into several sub-segments as mentioned below: Endoscope reprocessing solutions o Core equipment Automated Endoscope Reprocessors (AERs) Storage and Drying Cabinets o Consumables Disinfectants and Chemicals Detergents o Support Products Scope Transport Carts (Trays and Trolleys) Flushing Sinks Test Strips Cleaning Products (Wipes, Sponges, Brushes) Workflow Solutions o Integration Software Solutions o Track and Trace Solutions Endoscopy procedures, increasing at a healthy CAGR of 5.3%, will drive the usage of endoscope reprocessing systems such as AERs, storage and drying cabinets, consumables, and accessories in an otherwise saturated market. Ambulatory surgical centers (ASCs) have been taking increasing loads of endoscopic procedures in the US, accounting for 61% of the procedures in 2017. Commensurately, the number of ASCs with endoscopy capabilities has increased over the past four years. The significant shift in procedural volumes to outpatient and office-based settings has provided considerable new market opportunities for endoscopy reprocessing equipment and software vendors. The smaller volume requirements of small- to mid-sized ASCs provide strategic alternatives to market participants in terms of newer, smaller, and more efficient AER models such as pass-through AERs and off-the-shelf, turnkey and targeted software solutions with niche capabilities to monitor and track endoscopes and their inventory and repair needs, in addition to reprocessing and maintaining throughput. The ratio between the number of endoscope decontamination facilities to that of endoscopy suites in the US is estimated to be around 0.55, indicating 1 decontamination unit for 2 endoscopy units. This indicates huge market potential for specialized outsourcing services for endoscope reprocessing in the US. While we believe that smaller facilities do send their scopes for reprocessing to adjoining bigger facilities, there was no evidence of specialized players offering outsourcing of endoscope reprocessing in significant volumes. While outsourcing of endoscope reprocessing has been recently initiated as a service in the European market, Frost & Sullivan believes that it is going to be an early-stage market in the US by the end of forecast period. Market participants are expected to adopt significant strategic alternatives to find newer growth opportunities in an otherwise saturated market. Some of these include end-to-end endoscopy department management, portfolio expansions, innovative financing schemes, as well as offering breakthrough innovation in terms of AER technology, capable of disrupting the market. Thu, 21 Jun 2018 00:00:00 +0100 Novel Adeno-associated Virus Vectors Energizing Neuroscience http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-7E-00-00 This edition of the Genetic Technology TOE provides insights across new gene therapy technologies enabling enhanced management of neurological disorders. The service encompasses the impact and opportunity of gene therapy technologies in the neuroscience industry, while providing an overview of IP and R&D trends in this space. Additionally, this TOE analyzes gene therapy methods and profiles Voyager Therapeutics, US. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Adeno-associated virus gene therapy, AAV vector, gene delivery, biomanufacturing, neuroscience, central nervous system, Tauopathies, Alzheimer s disease, PSP, FTD, chronic pain, Friedreich s ataxia, Parkinson s disease, Huntington s disease, monogenic ALS Fri, 15 Jun 2018 00:00:00 +0100 Innovations in Implantable Devices, Anti-microbial Textiles, 3D Bioprinting, Cardiovascular Devices, and Bone Grafts http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-1E-00-00 The latest edition of Medical Device TOE captures innovations in the advanced medical technology (MedTech) space. The spectrum of innovations captured in this edition spans prosthetics, cardiovascular devices, 3D printed tissues, brain-computer interfaces for rehabilitation, and biologic grafts for orthopaedic applications. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Brain-computer interface, nanocoating, 3D bioprinting, anti-microbial textiles Fri, 15 Jun 2018 00:00:00 +0100